BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
BluePrint分子亚型可预测HER2阳性乳腺癌对新辅助帕妥珠单抗的反应
期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-023-01664-x
Liefaard, M C; van der Voort, A; van Ramshorst, M S; Sanders, J; Vonk, S; Horlings, H M; Siesling, S; de Munck, L; van Leeuwen, A E; Kleijn, M; Mittempergher, L; Kuilman, M M; Glas, A M; Wesseling, J; Lips, E H; Sonke, G S